Form 4: ALNY CFO Sells Shares for Tax Obligations

Alnylam Pharmaceuticals' EVP and CFO, Jeffrey V. Poulton, sold common stock on March 4, 2026, to cover tax withholding obligations from restricted stock unit vesting.

Summary

• Jeffrey V. Poulton, Executive Vice President and Chief Financial Officer of Alnylam Pharmaceuticals, Inc. (ALNY), reported transactions on March 4, 2026.
• Poulton sold a total of 2,468 shares of common stock across multiple transactions.
• These sales were mandatory 'sell-to-cover' provisions to satisfy statutory tax withholding obligations upon the vesting of restricted stock units.
• The sales occurred at weighted average prices ranging from $319.03 to $325.67 per share.
• Following these transactions, Poulton directly beneficially owns 61,805 shares of common stock.
• An additional 57 shares were indirectly acquired through a managed account (401(k) plan) as a result of the issuer's matching contribution program.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sales were non-discretionary and solely for tax purposes related to RSU vesting, which is a standard practice for executive compensation.

Positives

• Jeffrey V. Poulton acquired 57 shares of ALNY common stock indirectly through a managed 401(k) account due to the issuer's matching contribution program, increasing his overall beneficial ownership slightly.

Negatives

• Jeffrey V. Poulton's direct beneficial ownership of common stock decreased by 2,468 shares due to mandatory tax-related sales.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• Shares were automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units.

Industry Context

StockSavvy.ai notes that routine sell-to-cover transactions by executives, such as those reported in this Form 4, are common occurrences related to the vesting of equity compensation. These non-discretionary sales are typically executed to satisfy tax liabilities and generally do not signal a change in management's confidence or outlook on the company's prospects, unlike discretionary open-market sales.

Related Party Transactions

• The acquisition of 57 shares in a managed 401(k) account is a result of the issuer's matching contribution program, representing a standard employee benefit.

Stakeholder Impact

• Shareholders: The impact on shareholders is minimal, as the volume of shares sold is small relative to the company's total outstanding shares, and the sales were non-discretionary for tax purposes.

Key Dates

Recommendation

The reported transactions are routine, non-discretionary sales by an executive to cover tax obligations associated with restricted stock unit vesting. Such transactions do not reflect a change in the executive's confidence in the company's future or its operational performance. Therefore, the filing itself does not provide a basis for a change in investment recommendation.

Keywords

ALNY, Alnylam Pharmaceuticals, Form 4, Insider Transaction, Stock Sale, Tax Withholding, RSU Vesting, Jeffrey V. Poulton, CFO